Ryzneuta
Payments companies reported to CMS as associated with Ryzneuta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ryzneuta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ryzneuta
These are the largest totals companies reported as associated with Ryzneuta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| John Glaspy | Los Angeles, CA | Hematology & Oncology | $9,191.42 |
| Charles Leath | Birmingham, AL | Gynecologic Oncology | $6,054.70 |
| Hye Sook Chon | Tampa, FL | Gynecologic Oncology | $5,863.90 |
| Bradley Monk | West Palm Beach, FL | Gynecologic Oncology | $5,724.89 |
| Giuseppe Giaccone | Bethesda, MD | Hematology & Oncology | $5,457.44 |
| Thomas Stinchcombe | Chapel Hill, NC | Medical Oncology | $5,429.84 |
| Siddhartha Devarakonda | Seattle, WA | Medical Oncology | $4,930.80 |
| Ellsworth Grant | Los Angeles, CA | Hematology & Oncology | $62.68 |
| Michael Sherman | Walnut Creek, CA | Hematology & Oncology | $49.00 |
| Cheyenne Hardy | Olympia, WA | Physician Assistant | $46.11 |
Prescribed Ryzneuta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.